Be the first person to write a business review for Otsuka America, Inc.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.

Paladin Labs Inc. company's slate of prescription offerings includes drugs for urology, endocrinology, cancer, dermatology, neurology, and women's health. Among Paladin's key products are prostate cancer treatment Trelstar, testosterone deficiency drug Testim, and osteoarthritis therapy Pennsaid. The company also offers some over-the-counter (OTC) drugs in Canada, including emergency contraceptive Plan B. The company focuses on serving markets that are overlooked by larger pharmaceutical firms, typically by forming developing and marketing partnerships with other drugmakers.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Paratek Pharmaceuticals Inc. company is working to create new forms of tetracycline that will be effective against newly resistant strains of bacteria and potentially treat diseases not associated with bacteria, including neurodegenerative and inflammatory conditions such as rheumatoid arthritis. It has synthesized more than 2,500 new tetracycline compounds and is sifting through each to find their possible applications. The company's Multiple Antibiotic Resistance Program (MAR) is looking at ways to genetically turn off bacteria's ability to survive, thereby preventing infection in the first place.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.